Aims: EA-230 is a human chorionic gonadotropin hormone-derived linear tetrapeptide, developed for the treatment of systemic inflammation-related disorders.
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| INTRODUCTION
Systemic inflammation can arise due to a variety of infectious as well as non-infectious conditions such as sepsis, trauma and major surgical interventions. 1, 2 Although the immune response is essential for clearance of pathogens and initiation of tissue repair, a too persistent or overzealous response is detrimental and can lead to pronounced tissue damage with associated organ failure and mortality rates up to 30%. 3, 4 This is for instance exemplified by the high incidence of acute kidney injury (AKI) in systemic inflammation-related conditions, occurring in over a half of critically ill patients and in up to 30% of patients undergoing elective cardiac surgery. [5] [6] [7] [8] Despite its tremendous impact, no immunomodulatory interventions have proven to be effective in regulating the systemic inflammatory response to prevent organ injury. [9] [10] [11] Current strategies are confined to supportive treatment and novel strategies aimed at attenuating this exaggerated inflammatory response to prevent organ failure are therefore highly warranted.
EA-230 is a synthetic linear tetrapeptide (alanine-glutamine-glycine-valine; AQGV) derived from the β-chain of the human chorionic gonadotropin hormone (β-HCG). The discovery of this peptide finds its roots in the unique immunological situation encountered during pregnancy, in which the maternal immune system is adapted to tolerate the semi-allogeneic fetus without compromising pathogen clearing capacity. 12, 13 A striking hallmark of this immune-tolerant phenotype is attenuated disease activity of various autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and psoriasis during pregnancy and their relapse after delivery. [14] [15] [16] [17] HCG was shown to play a central role in this immune-tolerant adaption of the maternal immune system, [18] [19] [20] [21] which has led to the discovery of immune active fragments of the β-chain. These oligopeptides were found to circulate abundantly throughout pregnancy and to exert beneficial effects in various animals models of systemic inflammation, including attenuation of the inflammatory response, less organ failure and improved survival. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Of these peptides, the linear tetrapeptide AQGV (later named EA-230) strongly attenuated inflammation, preserved kidney function, and substantially reduced mortality in models of renal ischaemiareperfusion, 24 kidney transplantation, 25 and haemorrhagic- 28 and endotoxaemia-induced shock. 26 Following these encouraging preclinical results, we performed phase I studies with different dosing regimens that showed EA-230
to be well-tolerated with an excellent safety profile (reported elsewhere in this issue 32 ).
The present phase IIa study follows-up on our earlier results. In a randomized, double-blind, placebo-controlled study, we investigated the safety, efficacy and pharmacokinetics of EA-230 during experimen- What is already known about this subject
• EA-230 is a β-hCG-derived immunomodulatory tetrapeptide, developed for the treatment of systemic inflammation-related disorders.
• EA-230 was shown to reduce organ dysfunction and mortality in various animal studies of systemic inflammation.
• Phase I studies showed an excellent safety profile of EA-230 and pharmacokinetics analysis revealed a very short half-life and a large volume of distribution.
What this study adds
• No safety issues emerged in this phase IIa study in 36
volunteers.
• EA-230 attenuates the systemic inflammatory response in humans in vivo.
• Results of this study provide the basis for a patient study with EA-230.
the drug formulations used, history of spontaneous vagal collapse, significant blood loss within 90 days prior to the study, participation in any other clinical trial within 1 month prior to the study and participation in a previous trial in which LPS was administered. Prior to and during every study procedure, subjects were not allowed to use any medication, recreational drugs, nicotine, caffeine and/or alcohol.
Subjects were consecutively assigned to the 15, 45 or 90 mg/kg/h group, based on the order of their appearance on the study drug administration day. Dose regimens were based on the phase I studies using the same dosages without any safety concerns reported elsewhere in this issue. 32 Each dosage group consisted of 12 subjects;
within each dosage group subjects were randomly assigned to receive either EA-230 or placebo (n = 8 active study drug, n = 4 placebo) making use of a randomization list. All subjects underwent endotoxaemia in combination with EA-230 or placebo, as further detailed below.
The primary endpoint was safety and tolerability, assessed by the incidence of treatment related (serious) adverse events ([S]AEs).
Secondary endpoints included effects on the LPS-induced inflammatory response and pharmacokinetics. 
| Study medication

| Study procedures and experimental human endotoxaemia
A schematic overview of the study procedures is depicted in Figure 1 .
Study subjects were administered to a fully equipped research unit at the intensive care unit of the Radboud university medical centre.
The nondominant arm was cannulated for intravenous (i.v.) fluid administration and a 20-gauge arterial catheter was used for continuous blood pressure monitoring and blood sampling. As part of our standard endotoxaemia protocol, [33] [34] [35] subjects received a 1-hour infusion of 1.5 L prehydration solution (2.5% glucose/4.5% NaCl) starting at t = −1 h. At t = 0 h, LPS was administered, the intravenous cannula was flushed with 0.9% NaCl, and study drug treatment was initiated. 
| Safety
Safety and tolerability assessments were performed continuously from the start of study drug treatment until 8 hours afterwards and at 4 consecutive study visits during the 14-day follow-up period.
Safety parameters included vital signs (blood pressure and heart rate), 12-lead ECG and routine laboratory haematology and biochemistry.
AEs were recorded throughout the complete study period. All AEs were judged by the investigator with regard to severity (mild, moderate or severe) according to Common Terminology Criteria for Adverse Events guidelines 4.0, 36 and their relation to the study drug (definitely Nederland B.V., Etten-Leur, the Netherlands).
| Vital signs and endotoxaemia-induced symptoms
Heart rate, measured with a 3-lead ECG, and blood pressure were 
| Statistical analysis
The study was regarded as exploratory in nature and sample size was based on practical considerations, exposing a limited number of subjects while obtaining the necessary safety and efficacy data. (S)AEs are summarized by treatment group, preferred term, severity and relation to the study drug. Efficacy data are presented as mean ± standard error of the mean, demographic data as mean ± standard deviation. PK parameters are presented as geometric mean and 95%
confidence interval. Data were tested for normality using the Shapiro-Wilk test and a maximum normalized residual test according to Grubb was performed on efficacy data to identify significant outliers with a P < .01. Differences over time between EA-230-treated and placebo-treated subjects were compared by repeated measures 2-way ANOVA (interaction term: group*time). Baseline differences in demographic data were tested using a 1-way ANOVA. Dose proportionality of dose vs AUC 0-last , and C max was assessed using 1-way ANOVA followed by a Bonferroni posthoc test on dosenormalized, log-transformed data.
All statistical analyses were performed using GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA, USA). A 2-sided P-value <.05 was considered statistically significant.
3 | RESULTS
| Baseline characteristics and subject disposition
All study subjects received study medication according to the protocol and there were no relevant baseline differences between groups (Table 1) . One subject in the 90 mg/kg/h group was excluded from all efficacy analyses because of an unusually high cytokine response (significant outlier both within the 90 mg/kg/h group and in all groups combined for IL-6 and TNF-α [Grubb's test P < .01]) in combination with gastrointestinal complaints that were assessed as unlikely to be related to the study drug or endotoxin administration.
| Safety
A summary of all (S)AEs with severity and relation to the study treatment are listed in Table 2A and their preferred terms are organized per system organ class in Table 2B .
No SAEs were reported and infusion of EA-230 during experimental endotoxaemia was well-tolerated by all subjects across dosage groups without any safety concerns and/or discontinuation of study drug administration. Accordingly, no concerns were raised by the DSMB after completion of each dosing group.
Nineteen AEs were reported by 14 subjects, all of which were mild, transient and considered not, or unlikely to be, related to study drug treatment. Seven subjects (29%) treated with EA-230 and seven placebo-treated subjects (58%) reported ≥1 AE. Of all AEs, 9 were reported in the placebo group vs 10 in EA-230 treated subjects, 5 of which in the highest dosing group.
Other than the expected LPS-induced alterations in vital signs and leucocyte counts discussed below, alterations in laboratory parameters, vital signs and 12-leads ECG were considered not clinically significant.
| Effects of EA-230 on circulating levels of inflammatory mediators and adhesion molecules during endotoxaemia
The LPS-induced increase in plasma levels of inflammatory cytokines IL-6 and IL-1RA was significantly attenuated in subjects treated with Parameters were determined during screening visit. BMI: body mass index; HR: heart rate; MAP: mean arterial pressure. Data are presented as mean ± standard deviation. P-values were calculated using 1-way ANOVA. 
Any AE 
| Effects of EA-230 on vital signs and symptoms during endotoxaemia
Endotoxaemia resulted in fever (approximately an increase in body temperature of 2°C; Figure 6A ), development of influenza-like symptoms ( Figure 6B ), a decrease in mean arterial pressure (approximately 10 mmHg; Figure 6C ), and an increase in heart rate (approximately 30 beats/min; Figure 6D ). Fever peaked at 3-3.5 hours following LPS administration and was significantly lower in subjects treated with 90 mg/kg/h EA-230 compared to placebo (increase of 1.3 ± 0.2°C vs. 1.8 ± 0.1°C, respectively, at t = 3.5; Figure 6A ). Flu-like symptoms peaked at 1.5 hours after LPS administration and were approximately halved in subjects treated with 90 mg/kg/h EA-230 compared to placebo (4.0 ± 1.2 points vs. 7.4 ± 1.0 points respectively; Figure 6B ). The LPS-induced effects on mean arterial pressure and heart rate were not altered by EA-230 in any of the dosages (Supplemental data file 1). AE, adverse events; e, number of events; n, number of subjects.
| Pharmacokinetics of EA-230 during endotoxaemia
Plasma EA-230 concentration-time profiles and dose linearity are illustrated in Figure 7 . PK parameters are summarized in Table 3 . symptoms. These findings are in line with preclinical studies that demonstrated that EA-230 attenuates cytokine production, prevents tissue influx of neutrophils 24, 26, 28 and ameliorates inflammation-related clinical symptoms [24] [25] [26] 28 in various models of systemic inflammation.
Our data also reveal that, following the expected LPS-induced initial leucopenia (predominantly mediated by endothelial sequestration of lymphocytes and monocytes), the subsequent increase in numbers of circulating leucocytes (predominantly due to increased neutrophil numbers released from the bone marrow) was more pronounced in EA-230-treated subjects.
The substantial attenuation of the endotoxaemia-induced IL-6 response in EA-230-treated subjects may be of clinical relevance, as IL-6 is implicated to play a central role in various inflammatory disorders. As such, this cytokine is regarded to be a reliable marker reflecting the magnitude of systemic inflammation, e.g. following elective surgery 38 or in patients with pneumonia. 39 Furthermore, IL-6 levels are associated with organ failure and impaired (functional) outcome following severe injury, 40 cardiac surgery, 41 cardiac arrest, 42 stroke 43 and sepsis. 44 With respect to renal function, IL-6 plays a critical role in the development of AKI, 45 independently predicting mortality in patients starting dialysis 46 and predicting AKI following cardiac surgery. 41 In this perspective, our results are promising and EA-230 may show efficacy on these clinical endpoints in future studies.
Administration of EA-230 was well-tolerated throughout the conduct of the trial and no safety issues were raised during frequent independent interim safety analyses by the DSMB and in the final results. No dose-dependency for adverse events was observed and One subject was found to be a statistically significant outlier (per Grubb's test) and was excluded for the primary efficacy analyses.
When this volunteer was not excluded, the effects of EA-230 on clinical endpoints remained statistically significant, while the effects on some of the cytokines went from statistically significant to a trend.
Data on the pharmacokinetic profile of EA-230 reveal a large volume of distribution, a very rapid systemic clearance and accordingly a short half-life. A finding of interest is the substantially higher plasma concentrations of EA-230 compared to the phase I continuous dosing study reported elsewhere in this issue, 32 which was performed and analysed within the same institute, using exactly the same dosing regimens (15, 45 and 90 mg/kg/h for 2-hours). The elimination rates (β) were, however, comparable to those found in the phase I continuous dosage study. The observed increase in plasma concentrations are therefore accompanied responses. 47, 48 This markedly differs from clinical practice, where diseases associated with a systemic inflammatory response occur in people of all ages, both sexes, and are frequently complicated by 1 or more comorbidities as well as the use of comedication. Therefore, the generalizability of our results to the patient population remains to be determined. Third, although all PK parameters could be determined in all subjects of the highest dosing group, the pharmacokinetic characteristics of EA-230 (e.g. its very short half-life) precluded assessment of elimination constant-dependent parameters in several subjects of the lower dosage groups. However, in these subjects, plasma concentrations approaching zero (after approximately 5 times T 1/2 ) were reached within an hour, suggesting aT 1/2, of <0.2 h, which is in line with the data obtained in subjects in whom elimination constant-dependent parameters could be assessed. Finally, the exact mechanism(s) by which EA-230 modulates the immune response remain unclear and may have consequences for the optimal timing of administration. In the current study, steady-state concentrations EA-230 were present during the orchestration phase and peak (e.g. IL-6) of the inflammatory response.
In clinical practice, the timing of the inflammatory insult(s) is/are generally unknown and a subsequent more diffuse and longer lasting inflammatory response is often observed. Therefore, no definite conclusions regarding the optimal timing of administration of EA-230 for future clinical research can be drawn from this study.
In conclusion, the present proof-of-principle study demonstrates that EA-230 seems to be safe and attenuates the systemic inflammatory response in humans. Substantially higher plasma concentrations of EA-230 were observed in subjects with systemic inflammation compared to non-inflamed subjects, which was explained by a decrease in volume of distribution and clearance, but not by differences in the elimination constant. These inflammation-related effects on pharmacokinetic characteristics of EA-230 need to be further elucidated. The favourable safety profile of EA-230 and promising immunomodulatory results pave the way for a phase IIb clinical trial to assess the anti-inflammatory and tissue-protective effects of EA-230 in patients. 49 
